Healthcare
Australia's Quadrant exits Virtus Health, Summerset
Quadrant Private Equity has exited its investment in fertility services provider Virtus Health via a A$339 million ($330 million) IPO, while making another partial exit from retirement village chain Summerset.
Phillip PE sees 7x return on biotech start-up
Inviragen had inauspicious beginnings. The firm came about through a marriage of convenience between two biotech start-ups that couldn't get funding: US-based Inviragen was working on dengue fever vaccine but had no capital for clinical trials; over in...
UK drug developer Vectura partners PE on China JV
Vectura, a UK-based drug company, has teamed up with Hong Kong-based PE investor Zendex Bio Strategy and Tianjin KingYork Group to form a joint venture that will develop respiratory products in China and other Asian markets.
Goldman invests $20m in Indian medical device manufacturer
Goldman Sachs’ private equity unit has committed INR1.1 billion ($20 million) to BPL Medical Technologies, a subsidiary of listed Indian consumer products manufacturer BPL. This is Goldman's third investment in the Indian healthcare sector.
Hony-invested Biosensors completes bolt-on
Biosensors International, a Singapore-listed medical device company backed by Hony Capital, has acquired Spectrum Dynamics, an Israel-based medical imaging and clinical applications company, for $51.13 million.
IFC, Sabre to invest $40m in Everstone-backed Indian hospital chain
Ravindranath GE Medical Associates (RGE), which operates a chain of eight hospitals across India under the Global Hospitals brand, will receive $15 million from Sabre Partners and $25 million from the International Finance Corporation.
Japan's Takeda buys Singapore biopharma start-up
PE-backed Singapore biopharmaceutical start-up Inviragen is to be acquired by Japan's Takeda Pharmaceutical for $250 million.
Temasek-invested US drug developer targets IPO
Portola Pharmaceuticals, a US-based drug developer whose largest shareholder is Temasek Holdings, plans to raise $127 million through a NASDAQ IPO. The other backers include MPM Capital, Prospect Venture Partners, Brookside Capital, Sutter Hill Ventures,...
Quadrant-backed Summerset eyes Australia listing
Summerset, a New Zealand care home operator backed by Quadrant Private Equity, is seeking to list on the Australian Securities Exchange in response to increased interest from local investors.
Mercury takes 30% stake in Australia's Novotech
Mercury Capital has taken a 30% stake in Novotech, Australia's largest independent clinical trials provider, with a view to aiding its Asia-Pacific expansion. The amount invested was not disclosed.
Quadrant-backed Virtus Health launches IPO
Quadrant Private Equity-owned in-vitro fertilization (IVF) business Virtus Health launched its IPO road show on Monday. It is poised to be the largest equity offering since SCA Property in November last year and the biggest significant private equity-backed...
Fosun Pharma, Pramerica-Fosun buy Israel's Alma Lasers
Shanghai Fosun Pharmaaceutical, a subsidiary of China’s Fosun International, and the Pramerica-Fosun China Opportunity Fund, will be around $240 million to acquire up to 95.6% of Israel-based Alma Lasers.
Fortis healthcare raises $100m from IFC
Indian hospital and diagnostics group Fortis Healthcare is to issue 28.6 million shares to the International Finance Corporation (IFC) for a total of $45 million. Another $55 million will come through a private placement of foreign currency convertible...
CITIC-backed consortium sweetens deal for China 3SBio take-private
A consortium backed by CITIC Private Equity has raised its offer for the Chinese biotechnology company 3SBio to around $370 million.
SMC Capital closes $5m Series A round in Dalian Senyint
SMC Capital China, the early growth capital platform of veteran investor Simon Murray, has closed RMB30 million ($5 million) Series A investment in Dalian Senyint International Digital Medical System, a hospital IT solutions provider.
Somerset Indus invests in specialty hospital chain
Indian healthcare-focused PE firm Somerset Indus Capital Partners has invested in tertiary care hospital chain Cygnus Medicare. The investment will support the chain’s expansion across Haryana and the National Capital Region (NCR) surrounding Delhi.
Goldman, GIC invest $100m in China healthcare play iKang
Goldman Sachs and Government of Singapore Investment Corporation (GIC) have committed $100 million to Chinese private health management company iKang.
3SBio shareholder opposes CITIC PE-backed take-private
One of the largest shareholders of Chinese biotechnology firm 3SBio plans to oppose a take-private bid tabled by CEO Jing Lou and CITIC Private Equity that values the company at $340 million.
TPG completes take-private of China's ShangPharma
TPG Capital has completed a management buyout of ShangPharma Corporation that values the Chinese pharmaceutical and biotech research outsourcing firm at $173 million. It is the sixth private equity-backed privatization of a US-listed Chinese company to...
Australia VC: New faces
A new generation of VC firms is emerging in Australia, despite little appetite for the asset class from domestic LPs. Success hinges on leveraging Silicon Valley networks and targeting particular market niches
Qiming, KPCB lead $21.3m Series C investment in Origene
Qiming Venture Partners and KPCB China have led $21.3 million of Series C funding in OriGene Technologies, a biotech company based in the US and China.
Quadria Capital buys India's Milestone Religare
Quadria Capital, which is currently raising a healthcare fund focused on South Asia and Southeast Asia, has acquired Milestone Religare Investment Advisors. Milestone Capital, joint owner of the asset alongside Religare Enterprises, had been looking for...
CNEI invests in Chinese drug developer
China New Enterprise Investment (CNEI) has committed $21 million to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (FDZJ), a Hong Kong-listed developer of drugs and diagnostic products.
Temasek's Vertex leads Series B round for Clearbridge BioMedics
Vertex Ventures, a VC unit of Temasek Holdings, has led a Series B round of financing for Singapore-based Clearbridge BioMedics worth S$9 million ($7.2 million). Other participants include existing investor BioVeda, Spring Seeds Capital, Biosensors International...